- Home
- CRDF vs MMLP Comparison
CRDF vs MMLP Comparison
Compare CRDF & MMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- MMLP
- Stock Information
- Founded
- CRDF 1999
- MMLP 2002
- Country
- CRDF United States
- MMLP United States
- Employees
- CRDF N/A
- MMLP N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- MMLP Oil Refining/Marketing
- Sector
- CRDF Health Care
- MMLP Energy
- Exchange
- CRDF Nasdaq
- MMLP Nasdaq
- Market Cap
- CRDF 133.5M
- MMLP 155.2M
- IPO Year
- CRDF N/A
- MMLP 2002
- Fundamental
- Price
- CRDF $4.96
- MMLP $4.00
- Analyst Decision
- CRDF Strong Buy
- MMLP
- Analyst Count
- CRDF 3
- MMLP 0
- Target Price
- CRDF $10.33
- MMLP N/A
- AVG Volume (30 Days)
- CRDF 3.9M
- MMLP 90.8K
- Earning Date
- CRDF 11-07-2024
- MMLP 02-12-2025
- Dividend Yield
- CRDF N/A
- MMLP 0.50%
- EPS Growth
- CRDF N/A
- MMLP N/A
- EPS
- CRDF N/A
- MMLP 0.11
- Revenue
- CRDF $688,000.00
- MMLP $717,396,000.00
- Revenue This Year
- CRDF $23.78
- MMLP N/A
- Revenue Next Year
- CRDF N/A
- MMLP $0.80
- P/E Ratio
- CRDF N/A
- MMLP $37.37
- Revenue Growth
- CRDF 49.57
- MMLP N/A
- 52 Week Low
- CRDF $1.30
- MMLP $2.04
- 52 Week High
- CRDF $6.42
- MMLP $4.13
- Technical
- Relative Strength Index (RSI)
- CRDF 72.82
- MMLP 57.65
- Support Level
- CRDF $3.06
- MMLP $3.98
- Resistance Level
- CRDF $5.64
- MMLP $4.01
- Average True Range (ATR)
- CRDF 0.45
- MMLP 0.02
- MACD
- CRDF 0.29
- MMLP -0.00
- Stochastic Oscillator
- CRDF 84.32
- MMLP 75.00
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.